Amneal EU was granted FDA orphan designation for hydroxocobalamin as a treatment of known or suspected cyanide poisoning, according to a post to the agency’s website.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals announces submission of BLA to U.S. FDA for XOLAIR
- Amneal Pharmaceuticals Positioned for Significant Growth with Strong Product Momentum and Strategic Advantages
- Amneal Pharmaceuticals receives FDA approval for bimatoprost ophthalmic solution
- Amneal Pharmaceuticals price target raised to $14 from $12 at JPMorgan
- Amneal Pharmaceuticals receives FDA approval of sodium oxybate oral solution